132.31
price up icon0.01%   0.005
 
loading
전일 마감가:
$132.31
열려 있는:
$132.6
하루 거래량:
509.95K
Relative Volume:
0.33
시가총액:
$279.49B
수익:
$53.40B
순이익/손실:
$13.68B
주가수익비율:
19.21
EPS:
6.8864
순현금흐름:
$16.89B
1주 성능:
+1.03%
1개월 성능:
+3.34%
6개월 성능:
+27.42%
1년 성능:
+14.43%
1일 변동 폭
Value
$132.12
$132.91
1주일 범위
Value
$131.32
$133.55
52주 변동 폭
Value
$96.06
$133.55

노바티스 ADR Stock (NVS) Company Profile

Name
명칭
Novartis Ag Adr
Name
전화
-
Name
주소
-
Name
직원
75,883
Name
트위터
@novartis
Name
다음 수익 날짜
2025-07-17
Name
최신 SEC 제출 서류
Name
NVS's Discussions on Twitter

NVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.31 256.13B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
LLY
Lilly Eli Co
852.96 758.15B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
191.19 456.84B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
232.18 408.50B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.40 215.81B 63.43B 16.42B 14.72B 6.4861

노바티스 ADR Stock (NVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-09-12 다운그레이드 Goldman Neutral → Sell
2025-08-08 업그레이드 Morgan Stanley Underweight → Equal-Weight
2025-02-13 다운그레이드 UBS Buy → Neutral
2025-02-12 개시 Morgan Stanley Underweight
2025-02-04 업그레이드 Deutsche Bank Hold → Buy
2024-12-04 다운그레이드 HSBC Securities Hold → Reduce
2024-09-11 다운그레이드 BofA Securities Buy → Neutral
2024-09-05 다운그레이드 Goldman Buy → Neutral
2024-09-03 다운그레이드 Jefferies Buy → Hold
2024-07-19 다운그레이드 Deutsche Bank Buy → Hold
2024-05-30 개시 Goldman Buy
2024-02-23 개시 BMO Capital Markets Market Perform
2024-01-23 개시 Morgan Stanley Equal-Weight
2024-01-16 재개 UBS Buy
2023-12-18 다운그레이드 HSBC Securities Buy → Hold
2023-09-25 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-07-14 개시 HSBC Securities Buy
2023-04-26 업그레이드 Deutsche Bank Hold → Buy
2023-03-27 업그레이드 Deutsche Bank Sell → Hold
2023-01-26 다운그레이드 Citigroup Buy → Neutral
2022-12-05 업그레이드 Stifel Hold → Buy
2022-09-15 다운그레이드 Credit Suisse Neutral → Underperform
2022-09-14 다운그레이드 Berenberg Buy → Hold
2022-05-09 다운그레이드 Wolfe Research Outperform → Peer Perform
2022-01-10 재개 Citigroup Buy
2021-12-14 다운그레이드 Redburn Buy → Neutral
2021-12-06 다운그레이드 Exane BNP Paribas Outperform → Neutral
2021-12-03 다운그레이드 Bryan Garnier Buy → Neutral
2021-09-20 다운그레이드 Deutsche Bank Hold → Sell
2021-03-22 개시 Bernstein Mkt Perform
2021-03-10 다운그레이드 Argus Buy → Hold
2021-02-01 다운그레이드 Cowen Outperform → Market Perform
2021-01-15 개시 Deutsche Bank Buy
2020-09-29 개시 Berenberg Buy
2020-09-10 업그레이드 UBS Neutral → Buy
2020-09-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-15 업그레이드 Citigroup Neutral → Buy
2020-03-10 업그레이드 Morgan Stanley Underweight → Equal-Weight
2020-02-25 다운그레이드 Guggenheim Buy → Neutral
2019-04-25 업그레이드 Guggenheim Neutral → Buy
2019-04-25 업그레이드 Liberum Hold → Buy
2019-04-10 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2019-01-02 다운그레이드 JP Morgan Neutral → Underweight
2018-12-11 재개 Jefferies Buy
2018-10-09 개시 Guggenheim Neutral
2018-09-10 업그레이드 BofA/Merrill Underperform → Buy
2018-05-29 다운그레이드 HSBC Securities Buy → Hold
2018-05-25 업그레이드 Credit Suisse Underperform → Neutral
2018-01-25 재확인 Leerink Partners Outperform
2017-12-06 다운그레이드 BofA/Merrill Neutral → Underperform
2017-07-26 업그레이드 Morgan Stanley Underweight → Overweight
2017-07-05 다운그레이드 Credit Suisse Neutral → Underperform
2017-03-09 개시 Liberum Buy
모두보기

노바티스 ADR 주식(NVS)의 최신 뉴스

pulisher
Oct 08, 2025

Should You Buy Novartis Stock Before October 28? - Barchart.com

Oct 08, 2025
pulisher
Oct 08, 2025

Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances - GlobeNewswire Inc.

Oct 08, 2025
pulisher
Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com

Oct 04, 2025
pulisher
Sep 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis

Sep 29, 2025
pulisher
Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025
pulisher
Sep 25, 2025

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm

Sep 25, 2025
pulisher
Sep 23, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Sep 23, 2025
pulisher
Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025
pulisher
Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025
pulisher
Sep 13, 2025

UBS Sticks to Their Hold Rating for Novartis AG (NOVN) - The Globe and Mail

Sep 13, 2025
pulisher
Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025
pulisher
Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025
pulisher
Sep 11, 2025

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail

Sep 11, 2025
pulisher
Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025
pulisher
Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025
pulisher
Sep 09, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Sep 09, 2025
pulisher
Sep 04, 2025

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm

Sep 04, 2025
pulisher
Sep 04, 2025

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail

Sep 04, 2025
pulisher
Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025
pulisher
Aug 29, 2025

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm

Aug 29, 2025
pulisher
Aug 26, 2025

BioArctic and Novartis Sign an Option, Collaboration and License Agreement Using BrainTransporter for an Upfront Payment of USD 30 Million Plus Additional Potential Milestones and Royalties - 富途牛牛

Aug 26, 2025
pulisher
Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025
pulisher
Aug 19, 2025

Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail

Aug 19, 2025
pulisher
Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025
pulisher
Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025
pulisher
Aug 15, 2025

2 Dividend Stocks to Buy and Hold - sharewise.com

Aug 15, 2025
pulisher
Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025

노바티스 ADR (NVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general MRK
$87.41
price up icon 1.18%
drug_manufacturers_general NVO
$58.71
price down icon 1.53%
$296.51
price up icon 0.66%
$231.96
price up icon 0.32%
$117.92
price down icon 0.31%
자본화:     |  볼륨(24시간):